Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407293 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| SCHEMBL84168 | 1.00 | GRIA1 (0.39) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| Aspartic Acid SCHEMBL5964784 | 0.79 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL13319909 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL5290687 | 0.77 | GRIA1 (0.41) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL28471680 | 0.74 | GRIA1 (0.47) | GRIA1GRIA3GRIA2GRIA4GAA | |
| SCHEMBL4437211 | 0.72 | GRIA1 (0.36) | GRIA1GRIA3GRIA2GRIA4GAA | |
| Propionic Acid SCHEMBL4774389 | 0.67 | FFAR3 (0.37) | GRIA1GRIA3GRIA2GRIA4CACNA1F | |
| (S)-Ampa SCHEMBL667915 | 0.67 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL6809086 | 0.67 | CACNA1F (0.33) | CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| EP-1446501-A2 | METHODS FOR IDENTIFICATION OF CANCER CELL SURFACE MOLECULES AND CANCER SPECIFIC PROMOTERS, AND THERAPEUTIC USES THEREOF | Buadbo APS (DK) | 2004-08-18 | — | — | EP | claimed |
| WO-2003000928-A2 | METHODS FOR IDENTIFICATION OF CANCER CELL SURFACE MOLECULES AND CANCER SPECIFIC PROMOTERS, AND THERAPEUTIC USES THEREOF | BUADBO APS (DK) | 2003-01-03 | — | — | WO | claimed |
| US-20080286765-A1 | Human Obesity Susceptibility Gene Encoding a Taste Receptor and Uses Thereof | PHILIPPI ANNE | 2008-11-20 | — | — | US | disclosed |
| EP-1756315-A1 | HUMAN OBESITY SUSCEPTIBILITY GENE ENCODING A TASTE RECEPTOR AND USES THEREOF | Integragen (FR) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005123948-A1 | HUMAN OBESITY SUSCEPTIBILITY GENE ENCODING A TASTE RECEPTOR AND USES THEREOF | INTEGRAGEN (FR) | 2005-12-29 | — | — | WO | disclosed |
| US-6197771-B1 | NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6172065-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2001-01-09 | — | — | US | disclosed |
| US-6110911-A | ADMINISTERING NEUROPROTECTANT/ANTICONVULSANT TO PATIENT | WARNER-LAMBERT COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-6096744-A | ANTICONVULSANTS | WARNER-LAMBERT COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| US-6057313-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| US-6015800-A | Substituted quinoxaline-2-ones as glutamate receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5721234-A | TREATING CONVULSIONS, ANXIETY, CEREBRAL HYPOXIA/ISCHEMIA, PARKINSON*S DISEASE | WARNER-LAMBERT COMPANY (US) | 1998-02-24 | — | — | US | disclosed |